Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
复制标题
紫藤floribunda凝集素 - 亚苷粘蛋白核心多肽1是胆道癌和肝内胆管癌的敏感生物标志物：一项多中心研究。
DOI：
10.1007/s00535-016-1230-0
复制
发表时间：
2017-02
影响因子：
6.3
通讯作者：
Narimatsu H
中科院分区：
文献类型：
--
作者：
Shoda J;Matsuda A;Shida T;Yamamoto M;Nagino M;Tsuyuguchi T;Yasaka T;Tazuma S;Uchiyama K;Unno M;Ohkohchi N;Nakanuma Y;Kuno A;Narimatsu H
利用糖蛋白组学技术研究了花紫藤凝集素（WFA）-唾液酸化粘蛋白核心多肽1（MUC 1）作为胆管癌（CC）新的糖蛋白标志物。在这项多中心研究中，测定了血清和胆汁样本中的WFA-唾液酸化MUC 1水平，以确定其在胆道癌（BTC）和肝内（Ih）CC中的诊断能力。该研究包括244例BTC患者，59例IhCC患者，287例良性胆道疾病患者和44例对照组。BTC或IhCC患者的血清WFA唾液酸化MUC 1水平显著高于对照组和良性胆道疾病患者。IhCC患者的WFA-唾液酸化MUC 1水平高于其他部位肿瘤患者。没有显着差异，WFA-唾液酸化MUC 1水平被发现与癌症阶段或组织类型。受试者工作特征曲线分析显示，对于良性胆道疾病、BTC和IhCC以及I期和II期癌的诊断，WFA-唾液酸化MUC 1上级糖类抗原19-9（CA 19 -9）和癌胚抗原（CEA）。在BTC/IhCC中观察到比良性胆道疾病中显著更高水平的胆汁WFA唾液酸化MUC 1。胆汁中WFA-唾液酸化MUC 1对BTC/IhCC的诊断能力也上级CA 19 -9，诊断敏感性高于胆汁细胞学。WFA-唾液酸化MUC 1是BTC/IhCC的有用的新型生物标志物。在未来，这种测量应该应用于临床环境。
Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.